H.C. Wainwright initiated coverage of Aktis Oncology (AKTS) with a Buy rating and $30 price target The company is expanding the potential of targeted radiotherapy with its miniprotein platform, the analyst tells investors in a research note. These miniproteins exhibit an “ideal blend of properties,” including the ability to potently and selectively bind to a highly diverse set of tumor targets, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKTS:
- Aktis Oncology’s NECTINIUM-2 Trial: A New Radiopharma Bet in Solid Tumors
- Aktis Oncology: Fast-Track Momentum and Pipeline Catalysts Underpin Buy Rating and $34 Price Target
- Aktis Oncology receives U.S. FDA Fast Track Designation for AKY-1189
- Adobe downgraded, Palantir upgraded: Wall Street’s top analyst calls
- Aktis Oncology initiated with an Outperform at Leerink